MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
A Bolomsky, M Vogler, MC Köse, CA Heckman… - Journal of hematology & …, 2020 - Springer
Cell death escape is one of the most prominent features of tumor cells and closely linked to
the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic …
the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic …
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Y Xu, H Ye - Experimental Hematology & Oncology, 2022 - Springer
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
NCCN guidelines® insights: B-cell lymphomas, version 5.2021: featured updates to the NCCN guidelines
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-
Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as …
Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as …
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
P Jain, ML Wang - American journal of hematology, 2022 - Wiley Online Library
The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …
relentless advances in molecular pathogenesis, prognostication, and newer treatments …
Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma
PURPOSE Most patients with mantle cell lymphoma (MCL) are older. In this study, we
investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and …
investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and …
Targeting Bcl-2 for cancer therapy
L Zhang, Z Lu, X Zhao - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2021 - Elsevier
Apoptosis deficiency is one of the most important features observed in neoplastic diseases.
The Bcl-2 family is composed of a subset of proteins that act as decisive apoptosis …
The Bcl-2 family is composed of a subset of proteins that act as decisive apoptosis …
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis
Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is
subject to relapse and therapeutic resistance. Molecular aberrations in MCL affect …
subject to relapse and therapeutic resistance. Molecular aberrations in MCL affect …
Review of venetoclax in CLL, AML and multiple myeloma
M Lasica, MA Anderson - Journal of personalized medicine, 2021 - mdpi.com
Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is
able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be …
able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be …
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins
which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the …
which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the …
New directions for mantle cell lymphoma in 2022
Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and
biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the …
biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the …